GK and Hypoglycemia: A phase 1b/2 adaptive study with a 12‐week treatment duration demonstrated that hepatic GK activation could simultaneously decrease HbA1c, plasma β‐hydroxybutyrate, urinary ketones, and the frequency of severe or symptomatic hypoglycemia relative to placebo.51, 52